Recent Quotes (30 days)

You have no recent quotes
chg | %

Antibe Therapeutics Inc  

(Public, CVE:ATE)   Watch this stock  
Find more results for ATE
0.165
-0.015 (-8.33%)
Dec 8 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.17 - 0.18
52 week 0.10 - 0.27
Open 0.18
Vol / Avg. 47,111.00/57,537.00
Mkt cap 15.43M
P/E     -
Div/yield     -
EPS -0.05
Shares 93.52M
Beta -0.08
Inst. own     -
Feb 27, 2017
Q3 2017 Antibe Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 29, 2016
Q2 2017 Antibe Therapeutics Inc Earnings Release
Sep 13, 2016
Antibe Therapeutics Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q3 (Sep '16) 2016
Net profit margin -53.14% -59.30%
Operating margin -54.90% -78.80%
EBITD margin - -70.33%
Return on average assets -45.65% -49.98%
Return on average equity -100.17% -104.31%
Employees 3 -
CDP Score - -

Address

15 Prince Arthur Ave
TORONTO, ON M5R 1B2
Canada
+1-905-5705103 (Phone)

Website links

Description

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Officers and directors

Walter M. Macnee Independent Chairman of the Board
Age: 60
Daniel Legault J.D. President, Chief Executive Officer, Secretary, Director
Age: 56
John L. Wallace Ph.D. Founder, Chief Scientific Officer, Director
Age: 57
Alain S Wilson Chief Financial Officer
Jeremy Grushcow Executive Vice President - Strategic Development
David Vaughan Chief Development Officer
Age: 63
Samira Sakhia CPA Director
Yung Wu Director
Roderick J. Flower Ph.D. Independent Director
Age: 69
Jonathan Ross Goodman Independent Director
Age: 47